cgs 26303 has been researched along with Heart Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbier, S; Henry, JP; Jeng, AY; Monteil, C; Mulder, P; Renet, S; Thuillez, C | 1 |
| Emoto, N | 1 |
1 review(s) available for cgs 26303 and Heart Failure
| Article | Year |
|---|---|
[Physiological and pathophysiological roles of the endothelin converting enzymes].
Topics: Animals; Aspartic Acid Endopeptidases; Benzazepines; Benzofurans; Drug Design; Endothelin-Converting Enzymes; Glycopeptides; Heart Failure; Humans; Hypertension; Metalloendopeptidases; Mice; Mice, Knockout; Myocardial Infarction; Organophosphonates; Phenylalanine; Tetracyclines; Tetrazoles | 2004 |
1 other study(ies) available for cgs 26303 and Heart Failure
| Article | Year |
|---|---|
Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
Topics: Animals; Aspartic Acid Endopeptidases; Blood Pressure; Cardiac Output; Endothelin-Converting Enzymes; Heart Failure; Heart Rate; Male; Metalloendopeptidases; Neprilysin; Organophosphonates; Phenylalanine; Rats; Rats, Wistar; Tetrazoles; Ventricular Remodeling | 2004 |